Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 230

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 230
---
 Bio, Inc. (NASDAQ: UPB) since June 2023 and of CRISPR Therapeutics AG (NASDAQ: CRSP) since June 2021. In addition, Dr. Fleming is a member of the boards of directors of several private companies, including Komodo Health,
Inc., Orso Bio, Inc., Sudo Biosciences, Inc. and Egnite, Inc., and serves on the board of visitors of Vanderbilt’s School of Basic

170

Sciences. Dr. Fleming earned a B.A. in chemistry from Harvard University and an M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and
subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco. We believe Dr. Flemings’s extensive background in the healthcare industry and experience working closely with biopharmaceutical
companies provides him with the appropriate set of skills to serve as a member of our board of directors.

Lucian Iancovici, M.D., has
served as a member of our board of directors since December 2019. Dr. Iancovici is currently a managing director with TPG, a private equity investment firm, where he has worked since January 2018. From September 2012 to October 2017,
Dr. Iancovici served as the head of the Qualcomm Life Fund (“Qualcomm”), a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a
joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici has served on the board of directors of Rallybio Corp (NASDAQ: RLYB) since
May 2020 and serves on the boards of the following private companies: K2 Medical Research, Ceribell, Inc., Ellodi Pharmaceuticals and AnovoRx Holdings, Inc. Dr. Iancovici is a board certified internal medicine doctor who trained at Columbia
University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received a B.A. in economics and an M.D., both from Tufts University. We believe that Dr. Iancovici’s extensive experience in the
venture capital industry and his medical and scientific background and training provide him with the appropriate set of